drug

atebimetinib

1 story · latest Aug 5, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Immuneering Corporation

Timeline

Immuneering reports Q2 2026 results, MAPKeeper 301 dosing underway

Aug 5Quarterly updateImmuneering Corporation

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.